Fifth Lane Capital’s Ginkgo Bioworks DNA Stock Holding History

Fifth Lane Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-250	Closed	-$31K	–	191
2022 Q3	$31K	Buy	+250	New	+$29.8K	0.02%	78

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fifth Lane Capital's DNA Position: Q4 2022 in Review

Fifth Lane Capital sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 250 shares — an estimated $31K sold.

Fifth Lane Capital first reported a position in DNA in Q3 2022 and held it in 1 quarter. The position peaked at $31K in Q3 2022. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

Fifth Lane Capital reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
Fifth Lane Capital sold 250 Ginkgo Bioworks shares in Q4 2022, an estimated $31K.
Fifth Lane Capital first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 1 quarter.
Fifth Lane Capital's Ginkgo Bioworks position peaked at $31K in Q3 2022.
320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Fifth Lane Capital's 13F filing for Q4 2022, filed 14 Feb 2023.